Understanding Who Receives Trofinetide for Rett Syndrome in the U.S.
A study found that only about one-quarter of eligible individuals with Rett Syndrome received the newly approved medication, Trofinetide, shortly after its approval in the United States.
Research Profile
Published: June 11, 2026
Added to SpecialCircle: June 22, 2026
Evidence Level
Small human studyResearch Status
Approved treatmentKey takeaways
- •Trofinetide became the first approved medication for Rett Syndrome in the United States in March 2023.
- •About 26% of individuals identified with Rett Syndrome in this study received Trofinetide during the early period after its approval.
- •Individuals treated with Trofinetide were often younger (under 18), more frequently managed by child neurologists, and had more documented Rett-related features like loss of communication and motor skills.
- •Males and adults with Rett Syndrome were less likely to receive Trofinetide.
- •More research is needed to understand why many individuals with Rett Syndrome are not receiving this treatment and what barriers exist.
Source
Journal of health economics and outcomes research · Peer-reviewed study
Read the original sourcePlain-language summary
This study looked at real-world information to see who was receiving Trofinetide, the first approved medication for Rett Syndrome, after it became available in the US in March 2023. Researchers compared individuals with Rett Syndrome who received the medication to those who did not.
They found that only about a quarter of eligible people received Trofinetide, and these individuals were typically younger, often seeing a child neurologist, and had more clearly documented symptoms related to Rett Syndrome. The study highlighted that many adults and males with Rett Syndrome were not being treated with Trofinetide.
Why parents may care
This information is important for parents because it shows who is currently accessing a new, approved treatment for Rett Syndrome. If your child has Rett Syndrome, understanding these trends might help you discuss treatment options with your doctor and advocate for your child's care, especially if they are older or male.
What this means for daily life
The study suggests that younger individuals with clear Rett Syndrome symptoms might have an easier time accessing Trofinetide. For parents of older children or boys with Rett Syndrome, this research indicates there might be more challenges in getting this specific medication, requiring proactive discussions with healthcare providers.
What is still unknown
It is still unknown why a large proportion of eligible individuals, especially adults and males with Rett Syndrome, are not initiating Trofinetide treatment. The study calls for further understanding of the treatment pathways and barriers to starting this medication in routine Rett Syndrome care.
Frequently asked questions about Rett Syndrome
Trofinetide is the first pharmacologic treatment that was approved for Rett Syndrome in the United States in March 2023. This study examined its real-world use after approval.
Terminology glossary
- Rett Syndrome
- A rare neurological disorder that primarily affects females, leading to severe impairments in speech, purposeful hand use, and walking.
- Trofinetide
- The first medication approved in the United States specifically for the treatment of Rett Syndrome.
- Retrospective cohort study
- A type of research study that looks back at information collected in the past from a group of people to see how certain factors relate to outcomes.
- Pharmacologic treatment
- A type of treatment that involves the use of medication or drugs to manage a condition or disease.
- Comorbidity
- The presence of one or more additional medical conditions or diseases co-occurring with a primary disease or condition.
Questions to ask your doctor or therapist
- ?Is Trofinetide a suitable treatment option for my child's Rett Syndrome?
- ?What are the criteria for prescribing Trofinetide, and does my child meet them?
- ?What are the potential benefits and risks of Trofinetide for my child?
- ?How can we address any potential barriers to accessing this treatment for my child?
⚕️ This research digest is for educational and community support purposes only. It is not medical advice, diagnosis, or treatment. Always speak with a qualified doctor, therapist, or medical professional before making decisions about care.
Related research
Understanding Real-World Use of Trofinetide for Rett Syndrome
This study looked at how people with Rett syndrome in the United States used trofinetide, an FDA-approved treatment, over time.
Update on the NGN-401 Gene Therapy Study
Researchers have finished giving the study treatment to all 25 children in a major trial for a new gene therapy called NGN-401.
Brain Activity Differences in Visual Attention for Children and Teens with Autism
This study investigated how the brains of children and teenagers with autism process visual attention, finding specific differences in brain activity when focusing on the right side compared to typically developing peers.
FDA Discusses Paths to Earlier Gene Therapy for Children
The FDA recently hosted a workshop to find ways to get gene therapy into pediatric clinical trials sooner and more safely.
Talk to parents who truly understand
SpecialCircle is a free, private community. Ask questions, share what works, and never feel alone.